Related Experiment Video
Updated: May 8, 2026
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Pharmacodynamic and Toxicity Studies of 6-Isopropyldithio-2'-guanosine Analogs in Acute T-Lymphoblastic Leukemia
Tiantian Song1,2, Zheming Yu1, Qitao Shen2
1Institute of Drug Metabolism and Pharmaceutical Analysis, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
Abstract:
(1) Background: The research group has developed a new small molecule, 6-Isopropyldithio-2'-deoxyguanosine analogs-YLS004, which has been shown to be the most sensitive in acute T-lymphoblastic leukemia cells. Moreover, it was found that the structure of Nelarabine, a drug used to treat acute T-lymphoblastic leukemia, is highly similar to that of YLS004. Consequently, the structure of YLS004 was altered to produce a new small molecule inhibitor for this study, named YLS010. (2) Results: YLS010 has exhibited potent anti-tumor effects by inducing cell apoptosis and ferroptosis. A dose gradient was designed for in vivo experiments based on tentative estimates of the toxicity dose using acute toxicity in mice and long-term toxicity in rats. The study found that YLS010 at a dose of 8 mg/kg prolonged the survival of late-stage acute T-lymphoblastic leukemia mice in the mouse model study. (3) Conclusions: YLS010 has demonstrated specific killing effects against acute T-lymphoblastic leukemia both in vivo and in vitro. Preclinical studies of YLS010 offer a new opportunity for the treatment of patients with acute T-lymphoblastic leukemia in clinical settings.
Insights
A novel small molecule, YLS010, shows potent anti-cancer effects against acute T-lymphoblastic leukemia (T-ALL) by inducing apoptosis and ferroptosis. This compound significantly improved survival rates in preclinical models, offering a promising new therapeutic avenue for T-ALL patients.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- A novel small molecule, 6-Isopropyldithio-2'-deoxyguanosine analogs-YLS004, demonstrated high sensitivity in acute T-lymphoblastic leukemia (T-ALL) cells.
- YLS004 shares structural similarities with Nelarabine, an existing T-ALL therapeutic, prompting the development of a modified analog, YLS010.
Purpose of the Study:
- To investigate the anti-tumor efficacy and mechanisms of the novel small molecule YLS010.
- To evaluate the in vivo therapeutic potential of YLS010 in a preclinical model of acute T-lymphoblastic leukemia.
Main Methods:
- In vitro assessment of YLS010's effects on cancer cell apoptosis and ferroptosis.
- In vivo studies utilizing a mouse model of late-stage acute T-lymphoblastic leukemia to determine optimal dosage and efficacy.
- Acute and long-term toxicity assessments in mice and rats to establish a safe dose gradient for in vivo experiments.
Main Results:
- YLS010 demonstrated potent anti-tumor activity through the induction of both apoptosis and ferroptosis in cancer cells.
- In vivo studies showed that YLS010 at 8 mg/kg significantly prolonged the survival of mice with late-stage acute T-lymphoblastic leukemia.
- Preclinical toxicity studies informed the dose selection for in vivo efficacy trials.
Conclusions:
- YLS010 exhibits specific cytotoxic effects against acute T-lymphoblastic leukemia cells, both in vitro and in vivo.
- The findings support YLS010 as a promising candidate for further clinical development in the treatment of acute T-lymphoblastic leukemia.
More Related Videos
Related Concept Videos
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase